These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 19025986)

  • 1. Novel agents in myeloma: an exciting saga.
    Mark T; Niesvizky R; Coleman M
    Cancer; 2009 Jan; 115(2):236-42. PubMed ID: 19025986
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment paradigms for the newly diagnosed patient with multiple myeloma.
    Greipp P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S16-21. PubMed ID: 16344097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel agents for relapsed and/or refractory multiple myeloma.
    Thomas SK; Richards TA; Weber DM
    Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New drugs for multiple myeloma.
    Anderson KC
    Clin Adv Hematol Oncol; 2006 Aug; 4(8):592-4. PubMed ID: 17099617
    [No Abstract]   [Full Text] [Related]  

  • 5. [Multiple myeloma -- therapy].
    Jung W; Zettl F; Schroers R
    Dtsch Med Wochenschr; 2005 Feb; 130(6):283-6; quiz 287-90. PubMed ID: 15692903
    [No Abstract]   [Full Text] [Related]  

  • 6. Multiple myeloma therapies.
    Strobeck M
    Nat Rev Drug Discov; 2007 Mar; 6(3):181-2. PubMed ID: 17396289
    [No Abstract]   [Full Text] [Related]  

  • 7. Controversies regarding the use of dexamethasone in patients with multiple myeloma.
    Rajkumar SV
    Clin Adv Hematol Oncol; 2008 Feb; 6(2):103, 141. PubMed ID: 18347560
    [No Abstract]   [Full Text] [Related]  

  • 8. [Thalidomide treatment in multiple myeloma].
    Hattori Y
    Rinsho Ketsueki; 2003 May; 44(5):302-12. PubMed ID: 12822404
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel therapies in myeloma.
    Hayden PJ; Mitsiades CS; Anderson KC; Richardson PG
    Curr Opin Hematol; 2007 Nov; 14(6):609-15. PubMed ID: 17898564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New drugs for myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
    Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
    Anderson KC
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [It is not necessary to use novel agents to all patients with newly diagnosed myeloma as an initial therapy].
    Takamatsu Y
    Rinsho Ketsueki; 2012 Jun; 53(6):587-93. PubMed ID: 22790633
    [No Abstract]   [Full Text] [Related]  

  • 13. Bortezomib data show improved survival in patients with relapsed multiple myeloma.
    Oncology (Williston Park); 2004 Aug; 18(9):1199, 1201. PubMed ID: 15471202
    [No Abstract]   [Full Text] [Related]  

  • 14. Emerging drugs in multiple myeloma.
    Ghobrial IM; Leleu X; Hatjiharissi E; Hideshima T; Mitsiades C; Schlossman R; Anderson KC; Richardson P
    Expert Opin Emerg Drugs; 2007 Mar; 12(1):155-63. PubMed ID: 17355220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait.
    Badros A; Gahres N
    Clin Adv Hematol Oncol; 2005 Dec; 3(12):916-7; discussion 918. PubMed ID: 16555432
    [No Abstract]   [Full Text] [Related]  

  • 16. Frontline treatment of multiple myeloma in elderly patients.
    Moreau P; Hulin C; Facon T
    Blood Rev; 2008 Nov; 22(6):303-9. PubMed ID: 18550234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma.
    Zangari M; Esseltine D; Lee CK; Barlogie B; Elice F; Burns MJ; Kang SH; Yaccoby S; Najarian K; Richardson P; Sonneveld P; Tricot G
    Br J Haematol; 2005 Oct; 131(1):71-3. PubMed ID: 16173965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New agents and approaches in the treatment of multiple myeloma.
    Anderson KC
    Clin Adv Hematol Oncol; 2003 Mar; 1(3):151-2. PubMed ID: 16224394
    [No Abstract]   [Full Text] [Related]  

  • 19. Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials.
    Yaqub S; Ballester G; Ballester O
    Cancer Invest; 2013 Oct; 31(8):529-37. PubMed ID: 24083815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical management of myeloma--state of the art.
    Harousseau JL
    Cancer Treat Rev; 2010 May; 36 Suppl 2():S1-2. PubMed ID: 20472182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.